Lytix Biopharma Feed

	Est. tid*
2026-11-11	07:00	Kvartalsrapport 2026-Q3
2026-08-27	07:00	Kvartalsrapport 2026-Q2
2026-05-21	07:00	Kvartalsrapport 2026-Q1
2026-04-14	N/A	Årsstämma
2026-02-12	07:00	Bokslutskommuniké 2025
2026-01-26	-	Extra Bolagsstämma 2026
2025-11-18	-	Kvartalsrapport 2025-Q3
2025-08-28	-	Kvartalsrapport 2025-Q2
2025-05-15	-	Kvartalsrapport 2025-Q1
2025-04-30	-	X-dag ordinarie utdelning LYTIX 0.00 NOK
2025-04-29	-	Årsstämma
2025-02-13	-	Bokslutskommuniké 2024
2024-11-19	-	Kvartalsrapport 2024-Q3
2024-08-29	-	Kvartalsrapport 2024-Q2
2024-05-30	-	Kvartalsrapport 2024-Q1
2024-04-25	-	Extra Bolagsstämma 2024
2024-04-19	-	X-dag ordinarie utdelning LYTIX 0.00 NOK
2024-04-18	-	Årsstämma
2024-02-29	-	Bokslutskommuniké 2023
2023-11-09	-	Kvartalsrapport 2023-Q3
2023-08-31	-	Kvartalsrapport 2023-Q2
2023-05-11	-	Kvartalsrapport 2023-Q1
2023-04-19	-	X-dag ordinarie utdelning LYTIX 0.00 NOK
2023-04-18	-	Årsstämma
2023-02-16	-	Bokslutskommuniké 2022
2022-11-17	-	Kvartalsrapport 2022-Q3
2022-08-25	-	Kvartalsrapport 2022-Q2
2022-05-12	-	Kvartalsrapport 2022-Q1
2022-04-22	-	X-dag ordinarie utdelning LYTIX 0.00 NOK
2022-04-21	-	Årsstämma
2022-02-17	-	Bokslutskommuniké 2021

Land	Norge
Lista	Euronext Growth Oslo
Sektor	Hälsovård
Industri	Bioteknik

2026-02-10 19:04:17 Lytix Biopharma AS - Final result of Subsequent Offering and allocation of Offer Shares

2026-02-10 07:00:00 Lytix Biopharma AS - Last day of the Subscription Period in the Subsequent Offering

2026-02-05 12:33:43 Lytix Biopharma AS: Lytix Biopharma: Invitation to Q4 2025 Results Presentation and Publication of H2 2025 Report 9,30 NOK | -2,11% | 0,14 MNOK

2026-02-05 12:16:42 Lytix Biopharma: Invitation to Q4 2025 Results Presentation and Publication of H2 2025 Report 9,30 NOK | -2,11% | 0,14 MNOK

2026-01-27 10:49:48 Lytix Biopharma AS - Publication of Prospectus regarding Subsequent Offering and commencement of Subscription Period 9,00 NOK | 0,00% | 2,33 MNOK

2026-01-26 17:32:48 Lytix Biopharma AS - EGM minutes - Subsequent Offering, ASA Conversion, Board Expansion and Board Authorization Approved 9,00 NOK | 0,00% | 2,33 MNOK

2026-01-14 17:08:29 Lytix Biopharma AS - New share capital registered 9,20 NOK | -0,65% | 0,19 MNOK

2026-01-12 11:52:10 Lytix Biopharma AS - Notice of extraordinary general meeting 26 January 2026 9,50 NOK | 0,00% | 0,46 MNOK

2026-01-09 11:50:00 Lytix Biopharma AS - Mandatory notification of trade by close associate of primary insider 9,50 NOK | 0,00% | 1,59 MNOK

2026-01-09 07:58:27 Lytix Biopharma AS: Key information relating to potential subsequent offering 9,50 NOK | 0,00% | 1,59 MNOK

2026-01-09 07:49:16 Lytix Biopharma AS: Private placement successfully completed with oversubscription 9,50 NOK | 0,00% | 1,59 MNOK

2026-01-07 23:14:43 LYTIX: Financial calendar 9,50 NOK | 0,00% | 0,33 MNOK

2026-01-07 23:14:43 LYTIX: Finansiell kalender 9,50 NOK | 0,00% | 0,33 MNOK

2025-12-11 13:39:46 LYTIX BIOPHARMA AS - MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER 10,45 NOK | +8,18% | 1,16 MNOK

2025-11-18 07:00:00 Lytix Biopharma AS: Lytix Biopharma Q3 2025: Promising Results Accelerating Development Strategy 10,45 NOK | -9,13% | 1,93 MNOK

2025-11-18 07:00:00 Lytix Biopharma Q3 2025: Promising Results Accelerating Development Strategy 10,45 NOK | -9,13% | 1,93 MNOK

2025-11-14 07:05:00 Lytix Biopharma AS: Lytix Biopharma: Invitation to Q3 2025 Results Presentation 10,55 NOK | -3,65% | 1,33 MNOK

2025-11-14 07:00:00 Lytix Biopharma: Invitation to Q3 2025 Results Presentation 10,55 NOK | -3,65% | 1,33 MNOK

2025-11-11 07:00:00 Lytix Biopharma AS: Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital 10,70 NOK | -0,93% | 6,90 MNOK

2025-11-11 07:00:00 LYTIX: Lytix Biopharma kunngjør lovende interimdata fra NeoLIPA-studien ved Radiumhospitalet 10,70 NOK | -0,93% | 6,90 MNOK

2025-11-11 07:00:00 LYTIX: Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital 10,70 NOK | -0,93% | 6,90 MNOK

2025-11-10 07:00:00 Lytix Biopharma AS: New Phase II Study Data from Lytix Biopharma's Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide 10,80 NOK | +14,41% | 5,67 MNOK

2025-11-10 07:00:00 LYTIX: New Phase II Study Data from Lytix Biopharma's Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide 10,80 NOK | +14,41% | 5,67 MNOK

2025-10-10 11:46:11 LYTIX: Finansiell kalender 7,82 NOK | +2,09% | 0,29 MNOK

2025-10-10 11:46:11 LYTIX: Financial calendar 7,82 NOK | +2,09% | 0,29 MNOK

2025-10-08 07:05:00 Lytix Biopharma AS: Lytix Biopharma's licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025 7,54 NOK | +2,17% | 0,42 MNOK

2025-10-08 07:00:00 LYTIX: Lytix Biopharma's licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025 7,54 NOK | +2,17% | 0,42 MNOK

2025-09-01 19:55:43 Lytix Biopharma AS: Grant of share options to management and key personnel 7,78 NOK | +3,46% | 0,51 MNOK

2025-09-01 19:51:06 Lytix Biopharma AS: Grant of share options to management and key personnel 7,78 NOK | +3,46% | 0,51 MNOK

2025-08-28 07:07:00 Lytix Biopharma AS: Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with advancing clinical programs and strengthened organization 8,12 NOK | -10,18% | 1,87 MNOK

2025-08-28 07:00:00 Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with advancing clinical programs and strengthened organization 8,12 NOK | -10,18% | 1,87 MNOK

2025-08-21 14:08:51 Lytix Biopharma AS: Lytix Biopharma: Invitation to Q2 2025 Results Presentation 9,10 NOK | -2,36% | 0,11 MNOK

2025-08-21 13:53:51 Lytix Biopharma: Invitation to Q2 2025 Results Presentation 9,10 NOK | -2,36% | 0,11 MNOK

2025-05-21 16:05:02 Lytix Biopharma AS: GRANT OF SHARE OPTIONS 8,40 NOK | 0,00% | 2,09 MNOK

2025-05-15 07:05:00 Lytix Biopharma AS: Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phase III and broader pipeline progress 7,70 NOK | +22,22% | 10,3 MNOK

2025-05-15 07:00:00 Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phase III and broader pipeline progress 7,70 NOK | +22,22% | 10,3 MNOK

2025-05-09 07:10:00 Lytix Biopharma AS: Lytix Biopharma: Invitation to Q1 2025 Results Presentation 5,60 NOK | +4,48% | 0,19 MNOK

2025-05-09 07:00:00 Lytix Biopharma: Invitation to Q1 2025 Results Presentation 5,60 NOK | +4,48% | 0,19 MNOK

2025-04-29 14:27:01 Lytix Biopharma AS reshuffled its Board after the Ordinary General Meeting 5,30 NOK | -0,38% | 0,12 MNOK

2025-04-29 14:19:50 Lytix Biopharma AS: Minutes from Ordinary General Meeting and Election of New Board of Directors 5,30 NOK | -0,38% | 0,12 MNOK

2025-04-22 21:33:42 Lytix Biopharma AS: Recommendation from the Nomination and Compensation Committee to the Annual General Meeting, resignation by board Chair 5,38 NOK | +7,60% | 0,09 MNOK

2025-04-22 21:18:16 Lytix Biopharma AS: Recommendation from the Nomination and Compensation Committee to the Annual General Meeting, resignation by board Chair 5,38 NOK | +7,60% | 0,09 MNOK

2025-04-10 07:20:00 Lytix Biopharma AS: Notice of Annual General Meeting on 29 April 2025 4,87 NOK | -1,02% | 0,14 MNOK

2025-04-10 07:10:00 Lytix Biopharma AS: Notice of Annual General Meeting on 29 April 2025 4,87 NOK | -1,02% | 0,14 MNOK

2025-04-10 07:05:00 Lytix Biopharma AS: Annual Report for 2024 4,87 NOK | -1,02% | 0,14 MNOK

2025-04-10 07:00:00 Lytix Biopharma AS: Annual Report for 2024 4,87 NOK | -1,02% | 0,14 MNOK

2025-02-13 08:05:00 Lytix Biopharma AS: Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025 5,58 NOK | -2,45% | 0,73 MNOK

2025-02-13 08:00:00 Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025 5,58 NOK | -2,45% | 0,73 MNOK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Lytix Biopharma

Kalender

Beskrivning

Intresserad av bolagets nyckeltal?

Vem äger bolaget?

Lytix Biopharma

Kalender

Beskrivning

Intresserad av bolagets nyckeltal?

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden